LeenLife Pharma International Inc.

Suite 380 - 580 Hornby Street Vancouver, B.C., V6C 3B6



NEWSRELEASE

LeenLife Pharma International Announces Name Change

January 11, 2018 CSE - LLP

LeenLife Pharma International Inc. (the "Company" or "LeenLife") is pleased to announce the it will be changing it's Corporate name to **LeanLife Health Inc.** effective January 15, 2018. Effective at the opening of Trading January 15, 1018 the common shares of the Company will commence trading on the Canadian Stock Exchange (the "CSE") under the new name but it will continue under the same trading symbol "**LLP**" but will have a new Cusip number of 521855106.

As announced on January 3, 2018 the Company began the process of launching operations in the United States in preparation of setting up operations for production and sales in a location in the southeast area of Nevada. The Company has used the name "LeanLife" in its U.S. operations signifying a move using the correct spelling of the word "Lean" and feels that the name change for the Canadian company should also reflect that spelling.

Shareholders holding LeenLife share certificates can request a replacement certificate with the new Company name, but new certificates are not required and will not be automatically issued. There will be no consolidation of capital in connection with the change of name.

About the Company and the Market:

LeenLife products are extracted from flax seeds, a plentiful grain, an organic and a non-animal source. The products can be used as a food additive or as a nutraceutical and have been used in making bread, noodles, cheese, yogurt, juice and milk products for the European market. Their industry leading Omega 3 product formulations are of the highest quality with no cholesterol and toxic substances and are offered as an oil, emulsion and powder.

The global Omega 3 market was valued at 10 billion USD in 2016 and is expected to reach 16 billion USD by the end of 2023, growing at a CAGR of 7.57% between 2016 and 2023.

For more information, please contact:

Stan Lis, CEO Tel: 604 764-0518

E-mail: slis@leenlifepharma.com

Forward-looking Information

Certain statements included in this press release constitute forward-looking information or statements (collectively, "forward-looking statements"), including statements that address the Transaction and the meeting of shareholders and those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs and the ability to achieve goals.